Immune competent skin-on-chip platform for advanced wound healing studies
OneVivo is an innovative skin-on-chip system that replicates human skin's physiological environment for advanced wound healing research. It supports complex studies on cell viability, inflammation, and tissue remodeling, with unique gas regulation capabilities for precise modeling.
Overview
OneVivo is a cutting-edge skin-on-chip platform designed to simulate the intricate physiological conditions of human skin, making it ideal for advanced wound healing studies. It offers comprehensive tissue profiling, including cell viability, skin barrier competence, vasculature, and resident immune cells. This platform enables complex wound studies by assessing cell proliferation, migration, and inflammation, thereby providing significant insights into the wound healing process.
Technical specifications
- High-throughput system: Features 24 wells for simultaneous analysis of up to 24 skin samples, utilizing fresh skin from plastic surgery.
- Advanced imaging: Incorporates non-invasive image analysis alongside traditional techniques like RNASeq, H&E histology, and immunofluorescence imaging to quantify wound closure.
- Unique gas regulation: Fully controls physiological gases (CO2, O2, NO) above and below the skin, allowing detailed study of their impact on wound healing.
- Versatile application: Suitable for testing chemical burns, topical adhesives, bandages, and plasters.
Technology readiness level
The OneVivo platform is currently at TRL 2 for wound healing applications, indicating it is in the early stages of validation for this specific use case. The technology is well-characterized for supporting human skin tissue and has shown promising results in simulating various wound types, including chemical burns. Keratify is actively pursuing further validation through sponsored research collaborations to advance its development.
About Keratify
Keratify is a biotechnology company that provides a high-fidelity, ex vivo human skin testing platform designed to address the limitations of standard laboratory skin models. By maintaining whole human skin tissue in a lab environment, the company's patented technology allows for more accurate measurement of key biological processes, helping to overcome issues such as rapid tissue deterioration and poor predictive accuracy found in many 3D skin models and animal-based tests. The platform is designed to provide results that better mimic real human skin responses, which is critical for reducing errors in toxicology and compound testing.
This technology is particularly valuable for companies in the cosmetics, pharmaceutical, and medical device sectors that need to conduct dermatology research and development without relying on animal testing. By offering more reliable, human-relevant data, Keratify enables organizations to streamline their R&D processes, navigate regulatory requirements more effectively, and improve the development of new dermatological therapeutics and skin care products. The company currently provides these specialized capabilities through bespoke contract research services.
delivered to your inbox.